Rare non surgically correctable form of primary aldosteronism

Rare non-surgically correctable forms of primary aldosteronism encompass a group of conditions in which the adrenal glands produce excessive amounts of the hormone aldosterone, but unlike aldosterone-producing adenomas, these forms cannot be treated with surgical removal of a single adrenal gland. This category includes conditions such as bilateral adrenal hyperplasia (also called idiopathic hyperaldosteronism) and familial forms of hyperaldosteronism (including familial hyperaldosteronism types I, II, III, and IV). The excess aldosterone acts on the kidneys, causing the body to retain sodium and water while losing potassium, leading to high blood pressure (hypertension) that is often resistant to standard treatments, low potassium levels (hypokalemia), metabolic alkalosis, and associated symptoms such as muscle weakness, fatigue, headaches, and in some cases cardiac complications. The condition primarily affects the cardiovascular system, renal system, and electrolyte balance. Because surgical correction is not an option for these bilateral or diffuse forms, management relies on medical therapy, most notably mineralocorticoid receptor antagonists such as spironolactone or eplerenone, which block the effects of excess aldosterone. Additional antihypertensive medications may be required to achieve adequate blood pressure control. In familial hyperaldosteronism type I (glucocorticoid-remediable aldosteronism), low-dose glucocorticoids such as dexamethasone can suppress excess aldosterone production. Dietary sodium restriction and potassium supplementation may also be part of the management plan. Long-term monitoring is essential to prevent cardiovascular complications including stroke, heart failure, and kidney damage associated with chronic aldosterone excess.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Rare non surgically correctable form of primary aldosteronism